With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The company and the hospital will conduct a clinical study into the detection and prevention of the disease.
Oncgnostics will use MDxHealth's methylation-specific PCR in the GynTect test for cervical cancer, the fourth such test to use the technology.
Paired with Roche's HPV testing offerings, the deal will expand its cervical cancer testing capabilities.
The German-based company expects to file its test for FFPE within the next few months, and to start a clinical trial for its cytology test by mid-year.
Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.